duloxetine HCL

ApprovedSmall molecule

Eli Lilly

duloxetine HCL is one of 69 small molecule programs targeting Stress urinary incontinence. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stress Urinary IncontinenceActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

OsteoarthritisActive, not recruiting

Stress Urinary IncontinenceApproved

Active, not recruiting

Total Knee ArthroplastyApproved

Active, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

duloxetine HCL

Eli Lilly

Approved

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Toradol

Roche

Preclinical

1 4

Bayer Aspirin

Glucophage

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Benadryl

Western Medicine

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stress urinary incontinence1 trial

Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00190905·4,000 enrolled

Total Knee Arthroplasty1 trial

Pre-emptive Effect of Duloxetine in the Second Knee in Staged Total Knee Arthroplasty

Unknown status·SSeoul National University Hospital·Phase 4·NCT03792828·90 enrolled

Osteoarthritis1 trial

Duloxetine for Pain in Older Adults With Knee Osteoarthritis (OA)

Completed·UUniversity of Alexandria·N/A·NCT01425827·288 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for duloxetine HCL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — duloxetine HCL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for duloxetine HCL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

duloxetine HCL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stress urinary incontinence1 trial

Total Knee Arthroplasty1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News